鼻内新冠疫苗(Food and Drug Administration)(Intranasal COVID-19 vaccine(Food and Drug Administration))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制-

治疗领域

感染

在研适应症

冠状病毒感染

非在研适应症-

原研机构

US Food & Drug Administration

在研机构

US Food & Drug Administration

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与鼻内新冠疫苗(Food and Drug Administration) 相关的临床结果

登录后查看更多信息

100 项与鼻内新冠疫苗(Food and Drug Administration) 相关的转化医学

登录后查看更多信息

100 项与鼻内新冠疫苗(Food and Drug Administration) 相关的专利（医药）

登录后查看更多信息

1

项与鼻内新冠疫苗(Food and Drug Administration) 相关的文献（医药）

2023-01-01·Roczniki Panstwowego Zakladu Higieny

Intranasal (IN) COVID-19 vaccines - a breakthrough.

Article

作者: Kaur, Khushdeep ; Sood, Ridhima ; Singh, Balwinder ; Singh, Jyotsana ; Singh Gambhir, Ramandeep ; Matariya, Ridhi

Emerging variants of COVID-19 have threatened the effectiveness of intramuscular (IM) vaccines since that are made to target only the spike protein. Development of Intranasal (IN) vaccination has been proven to provide both the mucosal and systemic immune responses for broader and long lasting protection. Many IN vaccine candidates (virus-vectored vaccines, recombinant subunit vaccines and live attenuated vaccines) are in different phases of clinical trials and in near future many companies would be releasing their vaccines into the drug market. Potential advantages of IN vaccination over IM vaccination makes them ideal to be administered in children and developing populations of the world. This paper focuses on the very recent developments in intranasal vaccination with a spotlight on their safety and efficacy concerns. IN vaccination can prove to be game-changer in handling COVID-19 and potential viral contagious diseases in future.

100 项与鼻内新冠疫苗(Food and Drug Administration) 相关的药物交易

登录后查看更多信息